Literature DB >> 11785691

Iontophoretic delivery of ropinirole hydrochloride: effect of current density and vehicle formulation.

A Luzardo-Alvarez1, M B Delgado-Charro, J Blanco-Méndez.   

Abstract

PURPOSE: The objectives of this work were 1) to establish the feasibility of the transdermal iontophoretic delivery of ropinirole hydrochloride; 2) to investigate the possibility of delivering therapeutic doses of this drug; and 3) to determine the key factors that control ropinirole electrotransport.
METHODS: A series of in vitro transdermal iontophoretic experiments were instituted to study the effects of drug concentration, co-ion concentration, intensity of current, and application time on ropinirole flux. The convective contribution to ropinirole electrotransport was evaluated by following the transport of the electroosmotic marker mannitol.
RESULTS: Ropinirole flux decreased dramatically in the presence of competing ions. This effect was observed even when the molar fraction of the two competing cations was kept constant. Anodal flux of mannitol decreased with drug concentration, indicating a possible alteration of the skin permselectivity. In the absence of competing co-ions, ropinirole transport number reached a maximum value (8-13%). In these conditions, the main factor controlling drug delivery was the intensity of current applied.
CONCLUSIONS: Transdermal iontophoresis allowed the delivery of therapeutic doses of ropinirole. The dose administered and the input rate were controlled by the judicious choice of the key delivery factors here described.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11785691     DOI: 10.1023/a:1013322613436

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  15 in total

Review 1.  Pharmacologic profile of ropinirole: a nonergoline dopamine agonist.

Authors:  I F Tulloch
Journal:  Neurology       Date:  1997-07       Impact factor: 9.910

2.  Ropinirole for the treatment of early Parkinson's disease. The Ropinirole Study Group.

Authors:  C H Adler; K D Sethi; R A Hauser; T L Davis; J P Hammerstad; J Bertoni; R L Taylor; J Sanchez-Ramos; C F O'Brien
Journal:  Neurology       Date:  1997-08       Impact factor: 9.910

3.  Ropinirole without levodopa in Parkinson's disease.

Authors:  M J Vidailhet; A M Bonnet; S Belal; B Dubois; C Marle; Y Agid
Journal:  Lancet       Date:  1990-08-04       Impact factor: 79.321

4.  Transdermal delivery of peptides by iontophoresis.

Authors:  J Hirvonen; Y N Kalia; R H Guy
Journal:  Nat Biotechnol       Date:  1996-12       Impact factor: 54.908

5.  The safety of ropinirole, a selective nonergoline dopamine agonist, in patients with Parkinson's disease.

Authors:  A E Schrag; D J Brooks; E Brunt; D Fuell; A Korczyn; W Poewe; N P Quinn; O Rascol; F Stocchi
Journal:  Clin Neuropharmacol       Date:  1998 May-Jun       Impact factor: 1.592

6.  Iontophoretic delivery across the skin: electroosmosis and its modulation by drug substances.

Authors:  J Hirvonen; R H Guy
Journal:  Pharm Res       Date:  1997-09       Impact factor: 4.200

7.  Transport mechanisms in iontophoresis. II. Electroosmotic flow and transference number measurements for hairless mouse skin.

Authors:  M J Pikal; S Shah
Journal:  Pharm Res       Date:  1990-03       Impact factor: 4.200

8.  Convective solvent flow across the skin during iontophoresis.

Authors:  A Kim; P G Green; G Rao; R H Guy
Journal:  Pharm Res       Date:  1993-09       Impact factor: 4.200

9.  Characterization of convective solvent flow during iontophoresis.

Authors:  M B Delgado-Charro; R H Guy
Journal:  Pharm Res       Date:  1994-07       Impact factor: 4.200

Review 10.  Ropinirole: a review of its use in the management of Parkinson's disease.

Authors:  A J Matheson; C M Spencer
Journal:  Drugs       Date:  2000-07       Impact factor: 9.546

View more
  5 in total

1.  Electroosmotic pore transport in human skin.

Authors:  Olivia D Uitto; Henry S White
Journal:  Pharm Res       Date:  2003-04       Impact factor: 4.200

2.  Compartmental modeling of transdermal iontophoretic transport: I. In vitro model derivation and application.

Authors:  Akhmad Kharis Nugroho; Oscar Della Pasqua; Meindert Danhof; Joke A Bouwstra
Journal:  Pharm Res       Date:  2004-11       Impact factor: 4.200

3.  Transdermal iontophoresis of rotigotine across human stratum corneum in vitro: influence of pH and NaCl concentration.

Authors:  Akhmad Kharis Nugroho; Gai Ling Li; Meindert Danhof; Joke A Bouwstra
Journal:  Pharm Res       Date:  2004-05       Impact factor: 4.200

4.  Quantitative structure-permeation relationship for iontophoretic transport across the skin.

Authors:  Blaise Mudry; Pierre-Alain Carrupt; Richard H Guy; M Begoña Delgado-Charro
Journal:  J Control Release       Date:  2007-07-19       Impact factor: 9.776

5.  Transport numbers in transdermal iontophoresis.

Authors:  Blaise Mudry; Richard H Guy; M Begoña Delgado-Charro
Journal:  Biophys J       Date:  2006-01-27       Impact factor: 4.033

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.